Gilead Sciences to share drug data at ASH 2013

Gilead Sciences will be attending the upcoming American Society of Hematology (ASH) annual meeting in New Orleans, where it will present data from its oncology pipeline.

During the event from December 7th to 10th 2013, the company will present ten abstracts describing the company's investigational agents for several haematological malignancies.

This includes clinical and preclinical data from studies of idelalisib, which is currently under review in the US as a potential therapy for refractory indolent non-Hodgkin's lymphoma, as well as the latest findings on the investigational compounds GS-9973, GS-9820 and momelotinib.

Dr Roy Baynes, senior vice-president of oncology and inflammation therapeutics at Gilead Sciences, said: "We are moving forward quickly to fully explore the potential clinical benefit of idelalisib and other investigational agents against a range of haematological cancers."

This comes after the firm last week announced positive results from a trial of sofosbuvir, a new therapy for chronic hepatitis C patients who are co-infected with HIV.